Correction to: Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans, by Ellsworth JL, O'Callaghan M, Rubin H, and Seymour A.
{"title":"Correction to: Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans, by Ellsworth JL, O'Callaghan M, Rubin H, and Seymour A.","authors":"","doi":"10.1089/humc.2017.239.correx","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":51315,"journal":{"name":"Human Gene Therapy Clinical Development","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/humc.2017.239.correx","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Gene Therapy Clinical Development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/humc.2017.239.correx","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
期刊介绍：
Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
